POINT BIOPHARMA GLOBAL INC (PNT) Stock News
NASDAQ:PNT - Nasdaq - US7305411099 - Common Stock - Currency: USD
PNT Latest News, Press Relases and Analysis
Radiopharmaceutical market to reach ~$14B by 2032 (NYSE:LLY)
The international market for radiopharmaceuticals is projected to exceed $13.67B by 2032, with a compound annual growth rate of 10.2% from 2023. Read more here.
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain.
Fusion Pharma stock gains as Raymond James upgrades on M&A
Fusion Pharmaceuticals (FUSN) rises to a new 52-week high as Raymond James upgrades the biotech citing recent M&A activity in the radiopharma space. Read more here.
Eli Lilly completes $1.4B purchase of Point Biopharma
Eli Lilly completes its $1.4 billion acquisition of cancer drug developer Point Biopharma, solidifying its position in the pharmaceutical industry.
Mentions: LLY
Lilly Completes Acquisition of POINT Biopharma
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a...
Mentions: LLY
RBC says Bristol Myers/RayzeBio deal validates Fusion 's approach (NASDAQ:FUSN)
RBC Capital sees Bristol Myers' acquisition of RayzeBio as providing external validation for Fusion Pharmaceuticals' (FUSN) radiopharmaceutical approach. Read more here.
Eli Lilly purchase of Point Bio to close Wednesday after tender offer completed
Eli Lilly's $1.4 billion acquisition of Point Biopharma set to close as tender offer for the radiopharmaceutical company successfully completed.
Lilly extends tender offer for POINT Biopharma to Dec. 22 (NYSE:LLY)
Eli Lilly (LLY) has extended its tender offer to acquire POINT Biopharma (PNT) shares for $12.50 per share to Dec. 22. Read more here.
Mentions: LLY
Lantheus, Point BioPharma shares drop amid results of SPLASH study on prostate cancer
Lantheus Holdings and Point Biopharma saw stock prices drop after disappointing Phase 3 trial results for PNT2002, a lead candidate for prostate cancer...
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and...
Mentions: LLY
Eli Lilly surprised as POINT Biopharma deal is incomplete (NYSE:LLY)
Eli Lilly's (LLY) acquisition of radiopharmaceutical company POINT Biopharma (PNT) is facing challenges as investors show lack of interest. Read more here.
Mentions: LLY
Eli Lilly surprised as POINT Biopharma deal is incomplete
Eli Lilly's (LLY) acquisition of radiopharmaceutical company POINT Biopharma (PNT) is facing challenges as investors show lack of interest. Read more here.
Mentions: LLY
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and...
Mentions: LLY
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and...
Mentions: LLY
Point Biopharma stock gains amid regulatory OK, potential for increased Eli Lilly bid
Biotech company Point Biopharma's stock rises above deal price as its sale to Eli Lilly nears completion, gaining final regulatory approval.
Mentions: LLY
Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission ("NRC") has issued its consent for the indirect...
Mentions: LLY
POINT Biopharma Global GAAP EPS of -$0.23 beats by $0.07, revenue of $2.79M (NASDAQ:PNT)
POINT Biopharma Global reports Q3 2023 financial results, beating expectations with a GAAP EPS of -$0.23, exceeding estimates by $0.07, and generating...
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
Announced a definitive agreement to be acquired by Lilly for a purchase price of $12.50 per share in cash (an aggregate of approximately $1.4 billion);...
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments.
Eli Lilly extends expiration of tender offer to acquire Point Biopharma (NYSE:LLY)
Eli Lilly extends tender offer for Point Biopharma, just days after a major PNT shareholder objects to the deal between the parties. Read more here.
Mentions: LLY
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and...
Mentions: LLY
POINT Biopharma stock trades through deal price with Eli Lilly
POINT Biopharma's stock rises above its agreed upon deal price with Eli Lilly, potentially indicating anticipation of a rival bid.
